Capecitabine
Advanced Sarcoma
OHSU Knight Cancer InstituteSmall moleculePhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
109 Active assets in the Advanced Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BB |
Cyclophosphamide Essen Biotech | Phase 2 | BB |
Ifosfamide City of Hope Medical Center | Phase 3 | BB |
Inno-206 City of Hope Medical Center | Phase 3 | BB |
Carboplatin OHSU Knight Cancer Institute | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →